106 Additional Definitions Sample Clauses
The '106 Additional Definitions' clause serves to provide specific meanings for terms used throughout the contract that are not already defined elsewhere. This clause typically lists and clarifies the interpretation of particular words or phrases, ensuring that all parties have a shared understanding of key terminology. By establishing clear definitions, the clause helps prevent ambiguity and misunderstandings, thereby promoting consistency and reducing the risk of disputes over interpretation.
106 Additional Definitions. The following terms have the meanings set forth in the corresponding Sections of this Agreement: “AAA” 10.6.1
106 Additional Definitions. The following terms have the meanings set forth in the corresponding Sections of this Agreement: “Acceleron Indemnitees” 12.7.1
106 Additional Definitions. Each of the following definitions is set forth in the section of this Agreement indicated below: Actual Kolltan Development Costs 5.4.4 Auction License Agreement 5.4.3(e)(ii)
9.1 Auditing Party 6.9.1 Bankruptcy Code 2.4 Buyout Amount 5.4.1(b) Clinical and Research Supply Agreement 3.6.3(a) Co-Development and Co-Commercialization Agreement 5.4.1(c) Co-Development and Co-Commercialization Agreement Terms 5.4.1(c) Commercial Supply Agreement 3.6.4(a) Confidential Information 8.1 Court 12.2 Disclosing Party 8.1 Dispute 12.1 Effective Date Preamble Election Notice 5.4.1 Estimated Kolltan Development Costs 5.4.4 Exercise Notice 5.3.1(a) Existing Confidentiality Agreement 8.4 Expert 5.2.2(a) Final Kolltan Development Costs 5.4.4 Follow-On Product Transaction 2.5 Kolltan Preamble Kolltan ROFN Notice 2.5 Indemnified Party 10.3 Indemnifying Party 10.3 Indirect Taxes 6.9.3 Information Delivery Period 5.2.2(a) Inventory 3.6.1 Losses 10.1 Materials 3.6.1 MedImmune Preamble MedImmune ROFN Notice 2.5 Non-Paying Party 6.9.2 Option Period 5.3.1(a) Option Termination Date 3.5.2(a) Panel 5.2.2(a) Party or Parties Preamble Paying Party 6.9.1 Paying Party Withholding Tax Action 6.9.1 Product Acquisition Price Notice 5.2.2(b) Receiving Party 8.1 Resolution Period 12.1 Same or Later Stage Clinical Trial 12.4.2(a)(i) Selection Period 5.2.2(a) Sublicensed Rights 11.7.6 Third Party Transaction 5.5 Triggering Sale 12.4.2(a)(i) Trigger Period 5.2.1(a) Trigger Notice 5.2.1(a) Upfront Fee 6.1
106 Additional Definitions. The following terms have the meanings set forth in the corresponding Sections of this Agreement: “Acceleron Indemnitees” 12.7.1 “Acceleron NA Operating Costs” 5.5.3(b) “Acquired Party Activity” 6.3 “Audited Party” 5.7.4(b) “Auditing Party” 5.7.4(b) “Breaching Party” 11.2.1(a) “Celgene Indemnitees” 12.7.2 “Commercialization Plan/Budget” 2.5 “Defending Party” 8.4.3 “Forfeited Option Compound” 6.1.1 “Indemnitee” 12.7.3 “Infringement Claim” 8.4.1 “IP” 11.8 “JCC Chairperson” 3.2.3 “JDC Chairperson” 3.1.3 “Joint Development Committee” 3.1.1